Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199257 | 0.93 | PTPN1 (0.33) | F9 | |
| SCHEMBL20199252 | 0.91 | MCL1 (0.33) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL20174939 | 0.91 | MCL1 (0.33) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL20199238 | 0.91 | MCL1 (0.33) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL20199255 | 0.88 | S1PR5 (0.32) | — | |
| SCHEMBL20175152 | 0.86 | MCL1 (0.30) | F9 | |
| SCHEMBL20175162 | 0.83 | — | — | |
| SCHEMBL26284300 | 0.83 | — | — | |
| SCHEMBL26884913 | 0.82 | CA12 (0.40) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL20199231 | 0.82 | GPR84 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-09-22 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | CA12 2399/4885CA1 3361/4885CA2 3615/4885 |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | CA12 2399/4885CA1 3361/4885CA2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.